Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.
Summers
K
K
Stevens
J
J
Kakkas
I
I
Smith
M
M
Smith
L L
LL
Macdougall
F
F
Cavenagh
J
J
Bonnet
D
D
Young
B D
BD
Lister
T A
TA
Fitzgibbon
J
J
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004252:DNA Mutational Analysis; D017931:DNA Primers; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005188:False Negative Reactions; D005260:Female; D016162:Genes, Wilms Tumor; D005838:Genotype; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D050505:Mutant Proteins / Q000235:genetics* / Q000502:physiology; D016133:Polymerase Chain Reaction; D017434:Protein Structure, Tertiary / Q000235:genetics; D020080:Tandem Repeat Sequences; D017211:Treatment Failure; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D017931:DNA Primers; D050505:Mutant Proteins; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3